SCHEMBL150434

SCHEMBL150434

Nc1ccc(S(=O)(=O)Nc2ccc(C(=O)O)c(O)c2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.68
ALDH1A1 P00352 4/20 0.58
HSD17B10 Q99714 2/20 0.58
CA1 P00915 2/20 0.56
CA2 P00918 2/20 0.56
HTT P42858 1/20 0.56
CA9 Q16790 1/20 0.56
PTPN5 P54829 1/20 0.55
HPGD P15428 1/20 0.55
KMT2A Q03164 3/20 0.55
MEN1 O00255 2/20 0.55
PFKFB3 Q16875 3/20 0.54
MAPT P10636 2/20 0.54
CYP3A4 P08684 1/20 0.54
GAA P10253 1/20 0.54
ESR2 Q92731 1/20 0.54
KDM4E B2RXH2 1/20 0.54
PTPN1 P18031 1/20 0.54
KEAP1 Q14145 1/20 0.54
HTR6 P50406 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2565577 0.95 MCL1 (0.62) MCL1ALDH1A1HSD17B10CA1CA2
SCHEMBL9997330 0.87 MCL1 (0.70) MCL1ALDH1A1HSD17B10CA1CA2
SCHEMBL7828166 0.87 MCL1 (0.78) MCL1ALDH1A1HSD17B10PTPN5HPGD
SCHEMBL9997075 0.86 MCL1 (0.68) MCL1ALDH1A1HSD17B10PTPN5HPGD
SCHEMBL9997160 0.86 HSD17B10 (0.70) MCL1ALDH1A1HSD17B10PTPN5HPGD
SCHEMBL1130086 0.86 MCL1 (0.68) MCL1ALDH1A1HSD17B10CA1CA2
SCHEMBL9997215 0.84 MCL1 (0.74) MCL1ALDH1A1HSD17B10HTTPTPN5
SCHEMBL9997703 0.84 ALDH1A1 (0.67) MCL1ALDH1A1HSD17B10PTPN5HPGD
SCHEMBL11089286 0.84 KMT2A (0.56) MCL1ALDH1A1CA1CA2HTT
SCHEMBL9997237 0.83 APAF1 (0.67) MCL1ALDH1A1HSD17B10HTTPTPN5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4374848-A1 ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION Shanghai Bao Pharmaceuticals Co., Ltd. (CN) 2024-05-29 EP claimed
WO-2022040799-A1 ANTIMICROBIAL COMPOSITION GP TECH INOVASYON TEKNOLOJI VE ARASTIRMA A.S (TR) 2022-03-03 WO claimed
US-10449247-B2 Compositions and methods for enhancing immune response AVIVAGEN INC. (CA) 2019-10-22 US claimed
US-10092578-B2 Active agents and their oligomers and polymers POLYMERIX CORPORATION (US) 2018-10-09 US claimed
US-20170368185-A9 METHOD OF PREPARING DENDRITIC DRUGS CHAI MINGHUI (CN) 2017-12-28 US claimed
US-20160206746-A1 METHOD OF PREPARING DENDRITIC DRUGS CHAI MINGHUI (CN) 2016-07-21 US claimed
US-20150328323-A1 Nitric Oxide Releasing Produgs of Therapeutic Agents SATYAM APPARAO (IN) 2015-11-19 US claimed
US-8993117-B2 Devices with multiple surface functionality THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2015-03-31 US claimed
WO-2014111957-A1 NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS SATYAM APPARAO (IN) 2014-07-24 WO claimed
EP-2560634-A1 NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS Piramal Enterprises Limited (IN) 2013-02-27 EP claimed
EP-0741570-A1 METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS G.D. SEARLE & CO. (US) 1996-11-13 EP claimed
US-5543417-A 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent MERCK & CO., INC. (US) 1996-08-06 US claimed
WO-1996012487-A1 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO., INC. (US) 1996-05-02 WO claimed
WO-1996012817-A1 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO., INC. (US) 1996-05-02 WO claimed
WO-1995020387-A1 METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS G.D. SEARLE & CO. (US) 1995-08-03 WO claimed
EP-0572560-A4 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY. SHAPIRO HOWARD K (US) 1995-04-26 EP claimed
EP-0572560-A1 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO, Howard, K. (US) 1993-12-08 EP claimed
WO-1992014456-A1 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO HOWARD K (US) 1992-09-03 WO claimed
EP-0046270-B1 NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM INTERx RESEARCH CORPORATION (US) 1986-05-21 EP claimed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160206746-A1 METHOD OF PREPARING DENDRITIC DRUGS MYD88, TLR3, TLR6 MCL1 58/4885ALDH1A1 3848/4885HSD17B10 4676/4885
US-20170368185-A9 METHOD OF PREPARING DENDRITIC DRUGS MYD88, TLR3, TLR6 MCL1 58/4885ALDH1A1 3848/4885HSD17B10 4676/4885
US-20150328323-A1 Nitric Oxide Releasing Produgs of Therapeutic Agents NOS2, NOS1, PTGIS MCL1 1676/4885ALDH1A1 291/4885HSD17B10 1633/4885
US-10092578-B2 Active agents and their oligomers and polymers ALG1, DDOST, IDUA MCL1 1781/4885ALDH1A1 2906/4885HSD17B10 3062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.